Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial.
Loading...
Authors
Penault-Llorca, F
Dalenc, F
Chabaud, S
Cottu, P
Allouache, D
Cameron, D
Grenier, J
Venat Bouvet, L
Jegannathen, A
Campone, M
Issue Date
2024-04-30
Type
Journal Article
Clinical Trial, Phase III
Randomized Controlled Trial
Clinical Trial, Phase III
Randomized Controlled Trial
Language
en
Keywords
EndoPredict , breast cancer , endocrine therapy , prognostic biomarker , risk stratification , Wessex Classification Subject Headings::Oncology. Pathology.
Alternative Title
Abstract
The purpose of this study was to evaluate the prognostic value of the multigene EndoPredict test in prospectively collected data of patients screened for the randomized, double-blind, phase III UNIRAD trial, which evaluated the addition of everolimus to adjuvant endocrine therapy in high-risk, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.
Description
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Citation
Publisher
Elsevier
License
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.
Journal
ESMO open
Volume
9
Issue
5
PubMed ID
ISSN
2059-7029